SGC cancer gene therapy - Cyclacel
Latest Information Update: 18 May 2011
At a glance
- Originator University of Glasgow
- Class Gene therapies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Mar 2006 Xcyte Therapies has merged with Cyclacel to form Cyclacel Pharmaceuticals
- 03 Mar 2006 This programme is still in active development
- 23 Apr 1998 Preclinical development for Cancer in United Kingdom (Unknown route)